Watson launches generic Xopenex inhalation solution

Hannah Blake

pharmaphorum

Watson Pharmaceuticals has launched an authorized generic version of Xopenex (levalbuterol HCl) Inhalation Solution. This is part of an agreement Watson has with Sunovion Pharmaceuticals, who originally developed the drug, following its patent expiry in March 2012.

Xopenex Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

Xopenex had total US sales of approximately $474 million, between June 2011 and 2012, according to IMS Health data.